Cureduchenne Biobank
16 Oct
  • By Greg Freeman
  • Cause in

CureDuchenne Biobank

AUTHOR: Romina Foster-Bonds (View Spanish Version Below) CureDuchenne has made a significant commitment to develop and maintain a biobank dedicated to Duchenne muscular dystrophy — the CureDuchenne Biobank. The CureDuchenne Biobank will help clinicians and researchers spend their time doing what they do best — investigating important research questions. CureDuchenne is intimately connected to the […]

READ MORE
07 Oct
  • By Greg Freeman
  • Cause in

24th International Annual Congress of the World Muscle Society (WMS) Day 5 Blog

The last day 24th International Annual Congress of the World Muscle Society (WMS) opened with a talk touching on a growing field in neuromuscular disorders – the use of digital biomarkers to understand disease progression and whether interventions are effective.  This can include use of elaborate full body suits during clinic visits to capture entire […]

READ MORE
04 Oct
  • By Greg Freeman
  • Cause in

24th International Annual Congress of the World Muscle Society (WMS) Day 4 Blog

Many therapies being developed for Duchenne muscular dystrophy, including gene therapies, gene editing, and some exon-skipping approaches, rely on use of a virus to get the therapeutic components inside of muscle cells.  Since the most commonly used viruses for these purposes are AAVs (Adeno-Associated Viruses), many presentations covered AAVs at the 24th International Annual Congress […]

READ MORE
03 Oct
  • By Greg Freeman
  • Cause in

24th International Annual Congress of the World Muscle Society (WMS) Day 3 Blog

Even though it’s a conference of the World Muscle Society, the presentations on Thursday morning focused on the disease processes happening in parts of the body other than muscle.  This included a talk outlining the different ways scientists are trying to understand how the brain can be affected in cases of Duchenne muscular dystrophy (DMD). […]

READ MORE
World Muscle Society Day 2
03 Oct
  • By Greg Freeman
  • Cause in

24th International Annual Congress of the World Muscle Society (WMS) Day 2 Blog

Today was the first full day of research talks and posters at the 24th International Annual Congress of the World Muscle Society (WMS). It’s a busy meeting, with nearly 1,000 registered participants, 4 days of research talks, and over 570 research posters spread out among 5 different buildings.  As usual, updates in Duchenne Muscular Dystrophy […]

READ MORE
World Muscle Society
01 Oct
  • By Greg Freeman
  • Cause in

24th International Annual Congress of the World Muscle Society (WMS) Day 1 Blog

Greetings from Copenhagen, Denmark, where several members of the CureDuchenne team are attending the 24th International Annual Congress of the World Muscle Society (WMS).  This is the largest annual international research conference focused solely on neuromuscular diseases.  We are here because it’s an opportunity to hear about the latest research developments and network with others […]

READ MORE
19 Aug
  • By Greg Freeman
  • Cause in

There’s No Straight Line in Drug Development

Today’s FDA disapproval of Sarepta’s Vyondys 53 is disheartening, but a true example of just how difficult and costly the drug development process is.  We appreciate Sarepta’s efforts and dedication to helping those with Duchenne and are confident that Doug Ingram and his team will not let this slow them down. In drug development there […]

READ MORE
28 Jun
  • By Greg Freeman
  • Cause in

Summary of Pfizer Phase 1 Microdystrophin Gene Therapy Trial

Pfizer made their first public disclosure on early data from their open-label Phase 1 microdystrophin gene therapy trial for the treatment of Duchenne. The program was obtained from Pfizer’s acquisition of Bamboo Therapeutics, a Cure Duchenne funded company. Pfizer’s preliminary data is very encouraging despite two SAE’s which resolved with approved treatment. We are eager […]

READ MORE
25 Jun
  • By Sha
  • Cause in

Updates on CureDuchenne Gene Therapy Initiative

We are excited to report the progress of CureDuchenne’s Gene Therapy Initiative.  From our investment, as early as 2010, in Nationwide Children’s permanent duplication2 skipping program, to what has become Pfizer’s Duchenne gene therapy trial, to founding the first Duchenne gene editing company, Exonics (recently acquired by Vertex), to investing in crucial AAV manufacturing in […]

READ MORE